CA2121599A1 - Monoclonal antibodies directed against the microtubule-associated protein tau - Google Patents

Monoclonal antibodies directed against the microtubule-associated protein tau

Info

Publication number
CA2121599A1
CA2121599A1 CA002121599A CA2121599A CA2121599A1 CA 2121599 A1 CA2121599 A1 CA 2121599A1 CA 002121599 A CA002121599 A CA 002121599A CA 2121599 A CA2121599 A CA 2121599A CA 2121599 A1 CA2121599 A1 CA 2121599A1
Authority
CA
Canada
Prior art keywords
microtubule
monoclonal antibodies
directed against
antibodies directed
associated protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002121599A
Other languages
French (fr)
Other versions
CA2121599C (en
Inventor
Marc Mercken
Eva-Maria Mandelkow
Marc Vandermeeren
Eugeen Vanmechelen
Andre Van De Voorde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Original Assignee
Marc Mercken
Eva-Maria Mandelkow
Marc Vandermeeren
Eugeen Vanmechelen
Andre Van De Voorde
N.V. Innogenetics S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marc Mercken, Eva-Maria Mandelkow, Marc Vandermeeren, Eugeen Vanmechelen, Andre Van De Voorde, N.V. Innogenetics S.A. filed Critical Marc Mercken
Publication of CA2121599A1 publication Critical patent/CA2121599A1/en
Application granted granted Critical
Publication of CA2121599C publication Critical patent/CA2121599C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Abstract

A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau proteine. The tau protein can be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.
CA002121599A 1991-10-25 1992-10-17 Monoclonal antibodies directed against the microtubule-associated protein tau Expired - Lifetime CA2121599C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP91402871.7 1991-10-25
EP91402871 1991-10-25
PCT/EP1992/002392 WO1993008302A1 (en) 1991-10-25 1992-10-17 Monoclonal antibodies directed against the microtubule-associated protein tau

Publications (2)

Publication Number Publication Date
CA2121599A1 true CA2121599A1 (en) 1993-04-29
CA2121599C CA2121599C (en) 2007-04-10

Family

ID=8208630

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002121599A Expired - Lifetime CA2121599C (en) 1991-10-25 1992-10-17 Monoclonal antibodies directed against the microtubule-associated protein tau

Country Status (10)

Country Link
US (4) US6238892B1 (en)
EP (1) EP0610330B1 (en)
JP (2) JP3909084B2 (en)
AT (1) ATE154642T1 (en)
AU (1) AU662178B2 (en)
CA (1) CA2121599C (en)
DE (1) DE69220503T2 (en)
DK (1) DK0610330T3 (en)
GR (1) GR3024635T3 (en)
WO (1) WO1993008302A1 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811310A (en) * 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
AU662178B2 (en) 1991-10-25 1995-08-24 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau
JPH06239899A (en) * 1993-02-12 1994-08-30 Teijin Ltd Antibody for human tau protein and determination of human tau protein in body fluid utilizing the same
PT737208E (en) * 1993-12-21 2006-12-29 Innogenetics Nv Monoclonal antibodies specific for phf-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications
ATE234324T1 (en) * 1994-07-29 2003-03-15 Innogenetics Nv MONOCLONAL ANTIBODIES TO AN EPITOPE OF A CERTAIN SUBCLASS OR FORM OF PHOSPHORYLATED TAU, HYBRIDOMAS THAT SECRETE THEM, ANTIGEN RECOGNITION BY THESE ANTIBODIES AND THEIR USE
JP3671440B2 (en) 1994-09-16 2005-07-13 株式会社デンソー Torque transmission device
US6718053B1 (en) * 1996-11-27 2004-04-06 Chromavision Medical Systems, Inc. Method and apparatus for automated image analysis of biological specimens
DE69627183T2 (en) * 1995-11-30 2004-01-29 Chromavision Med Sys Inc PROCESS FOR THE AUTOMATIC IMAGE ANALYSIS OF BIOLOGICAL SAMPLES
US20020102553A1 (en) * 1997-10-24 2002-08-01 University Of Rochester Molecular markers for the diagnosis of alzheimer's disease
US20050084875A1 (en) * 1997-10-24 2005-04-21 University Of Rochester Molecular markers for the diagnosis of Alzheimer's disease
US6797478B1 (en) 1998-03-05 2004-09-28 University Of Cincinnati Method of detecting axonal damage, from associated disease states using tau monoclonal antibodies
CA2340433A1 (en) * 1998-09-08 2000-03-16 Innogenetics N.V. Tau as a marker for early cns damage
US7146209B2 (en) * 2000-05-08 2006-12-05 Brainsgate, Ltd. Stimulation for treating eye pathologies
AU2002361618A1 (en) * 2001-11-13 2003-05-26 Chromavision Medical Systems, Inc. A system for tracking biological samples
US7684859B2 (en) * 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
CA2483635A1 (en) * 2002-04-25 2003-11-06 Alon Shalev Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head
US20050037406A1 (en) * 2002-06-12 2005-02-17 De La Torre-Bueno Jose Methods and apparatus for analysis of a biological specimen
US7272252B2 (en) * 2002-06-12 2007-09-18 Clarient, Inc. Automated system for combining bright field and fluorescent microscopy
AU2003283786A1 (en) * 2002-11-14 2004-06-03 Brainsgate Ltd. Surgical tools and techniques for stimulation
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
US20040202357A1 (en) 2003-04-11 2004-10-14 Perz Cynthia B. Silhouette image acquisition
US7238788B2 (en) * 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US7653260B2 (en) * 2004-06-17 2010-01-26 Carl Zeis MicroImaging GmbH System and method of registering field of view
US8582924B2 (en) * 2004-06-30 2013-11-12 Carl Zeiss Microimaging Gmbh Data structure of an image storage and retrieval system
WO2006021957A2 (en) * 2004-08-23 2006-03-02 Brainsgate Ltd. Concurrent bilateral spg modulation
US20070031043A1 (en) * 2005-08-02 2007-02-08 Perz Cynthia B System for and method of intelligently directed segmentation analysis for automated microscope systems
PT1976877E (en) 2005-11-30 2014-04-29 Abbvie Inc Monoclonal antibodies against amyloid beta protein and uses thereof
EP1954718B1 (en) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20090210026A1 (en) * 2006-08-17 2009-08-20 Brainsgate Ltd. Spg stimulation for enhancing neurogenesis and brain metabolism
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
CA2714600C (en) 2008-02-29 2021-11-02 Dako Denmark A/S Systems and methods for tracking and providing workflow information
CN106390107B (en) 2009-06-10 2019-12-31 纽约大学 Immune targeting of pathological TAU proteins
BR112012008381A2 (en) * 2009-09-24 2017-06-13 Inserm (Institut Nat De La Santé Et De La Rech Médicale) fkbp52-tau interaction as a new therapeutic target to treat neurological disorders involving tau dysfunction
WO2011053565A2 (en) * 2009-10-29 2011-05-05 Biomedical Sciences Research Centre "Alexander Fleming" Compositions and methods for detecting a tauopathy
US9012237B2 (en) 2009-11-17 2015-04-21 Servicios Cientificos Neuroinnovation Limitada Innovative blood platelets biomarker for early diagnosis of alzheimer's disease
JP2013523182A (en) 2010-04-15 2013-06-17 アボット・ラボラトリーズ Amyloid beta-binding protein
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
ES2686550T3 (en) * 2010-10-11 2018-10-18 Biogen International Neuroscience Gmbh Human anti-tau antibodies
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
SI2794654T1 (en) * 2011-12-20 2019-08-30 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
KR102494798B1 (en) 2012-07-03 2023-02-06 워싱턴 유니버시티 Antibodies to tau
SI2885010T1 (en) 2012-08-16 2020-07-31 Ipierian, Inc. Methods of treating a tauopathy
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
MX2015008024A (en) * 2012-12-21 2016-08-08 Biogen Int Neuroscience Gmbh Human anti-tau antibodies.
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
EP2878335B1 (en) 2013-11-10 2018-01-03 Brainsgate Ltd. Implant and delivery system for neural stimulator
WO2015122922A1 (en) 2014-02-14 2015-08-20 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
TWI734975B (en) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 Humanized anti-tau antibodies
DE102014013571A1 (en) 2014-09-18 2016-03-24 Aj Roboscreen Gmbh Monoclonal antibody to human TAU protein
EP3093043B1 (en) 2015-05-13 2018-11-14 Brainsgate Ltd. Implant and delivery system for neural stimulator
MA42380A (en) 2015-07-06 2018-05-16 Ucb Biopharma Sprl ANTIBODIES BONDING TO TAU
KR20190134997A (en) * 2017-02-17 2019-12-05 데날리 테라퓨틱스 인크. Anti-TAU Antibodies and Methods of Use thereof
JOP20180021A1 (en) 2017-03-16 2019-01-30 Janssen Biotech Inc Anti-phf-tau antibodies and uses thereof
WO2019118906A2 (en) 2017-12-14 2019-06-20 University Of Florida Research Foundation Monoclonal antibodies targeting phf1 and at8 epitopes of human tau protein
EP4271708A1 (en) 2020-12-29 2023-11-08 Neurimmune AG Human anti-tau antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811310A (en) * 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
US5733734A (en) * 1991-08-14 1998-03-31 The Trustees Of The University Of Pennsylvania Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments
AU662178B2 (en) 1991-10-25 1995-08-24 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau
AU690092B2 (en) * 1992-12-14 1998-04-23 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
PT737208E (en) * 1993-12-21 2006-12-29 Innogenetics Nv Monoclonal antibodies specific for phf-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications

Also Published As

Publication number Publication date
US20060008853A1 (en) 2006-01-12
AU2800292A (en) 1993-05-21
DE69220503D1 (en) 1997-07-24
US6900293B2 (en) 2005-05-31
US8163873B2 (en) 2012-04-24
US20090137051A1 (en) 2009-05-28
EP0610330B1 (en) 1997-06-18
ATE154642T1 (en) 1997-07-15
EP0610330A1 (en) 1994-08-17
US20110143443A9 (en) 2011-06-16
JP3909084B2 (en) 2007-04-25
GR3024635T3 (en) 1997-12-31
CA2121599C (en) 2007-04-10
DE69220503T2 (en) 1998-02-05
WO1993008302A1 (en) 1993-04-29
JPH07502888A (en) 1995-03-30
JP2004043487A (en) 2004-02-12
US20010018191A1 (en) 2001-08-30
DK0610330T3 (en) 1998-01-26
US6238892B1 (en) 2001-05-29
AU662178B2 (en) 1995-08-24

Similar Documents

Publication Publication Date Title
CA2121599A1 (en) Monoclonal antibodies directed against the microtubule-associated protein tau
EP0394946A3 (en) Human monoclonal antibody, and its production and use
DK0673418T3 (en) Monoclonal antibodies directed against microtubule-associated tau protein, hybridomas secreting these antibodies, antigen
EP0909814A3 (en) Use of protein kinases for the diagnosis and treatment of Alzheimer's disease
AU2097692A (en) Method for the production of monoclonal antibodies utilizing a germfree animal
AU3287989A (en) Antibodies to a4 amyloid peptide
AU8185494A (en) Diagnostic assay for alzheimer's disease
CA2212150A1 (en) Monoclonal antibodies for human osteogenic cell surface antigens
GR3025630T3 (en) Monoclonal antibody against human IgE
EP0350690A3 (en) Neutralisation of the in vitro and in vivo toxic properties of tnf-alpha by monoclonal antibodies and by fragments derived therefrom
AU5809290A (en) Monoclonal antibodies involved in alzheimer's disease, hybridomas secreting these monoclonal antibodies, antigen recognized by these antibodies, and their application
NO972522L (en) Monoclonal antibodies with immunosuppressive activity
PL314414A1 (en) Antiidiotypic antibodies capable to induce an immunological response in respect to the receptor of epidermis growth factor
AU2070688A (en) Antigen recognized by mca 16-88
EP0537168A4 (en) Ctaa 28a32, the antigen recognized by mca 28a32
CA2150816A1 (en) Monoclonal antibodies directed against the microtubule- associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and theirapplications
AU1626492A (en) Monoclonal antibodies against the plasmin-antiplasmin complex, a method for the preparation thereof and the use thereof
WO2001032692A3 (en) Peptide mimics of conserved gonococcal epitopes and methods and compositions using them
GR3007245T3 (en)
WO1998027999A3 (en) Anti-allergenic compounds for the treatment of immune diseases containing haptenized antigen antibody complexes
EP0450573A3 (en) Antibodies for the treatment and diagnosis of pseudomonas aeruginosa infections
CA2151945A1 (en) Assay and treatment for demyelinating diseases such as multiple sclerosis
Predy Characterization of novel antigens, detected using monoclonal antibodies raised against tissue from the central nervous system of multiple sclerosis patients
Vlasenko et al. Regulation of immunoglobulin production by myelopide in peripheral blood lymphocyte culture from normal individuals and pattents with a secondary immunodeficiency state
Ritter et al. Immunogenicity of bovine brain gangliosides in Lewis rats with ean

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry
MKEX Expiry

Effective date: 20121017